Prof. Dr. Kristian Reich, Germany
The novel class of IL-23p19 inhibitors
The forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research.
The presentation of Prof. Dr. Kristian Reich is going to highlight the tong-term efficacy of Guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: Results from VOYAGE 2
Saturday, 17th of February 2018,
1pm to 3pm, Ballroom 20A